Paper 3 : Yale Researchers Use Phage Therapy to Target Drug-Resistant Infections in Cystic Fibrosis Patients

-

Researchers at Yale University have reported promising results using phage therapy to treat drug-resistant bacterial infections in adults with cystic fibrosis, a disease where chronic lung infections remain one of the leading causes of respiratory decline and mortality. Published in Nature Medicine, the study highlights a personalized bacteriophage strategy designed not only to eliminate pathogenic bacteria, but also to force surviving bacterial populations into less virulent and more antibiotic-sensitive states.

The research focused primarily on Pseudomonas aeruginosa, one of the most problematic pathogens in cystic fibrosis patients. This bacterium is highly adapted to the mucus-rich lung environment characteristic of the disease and frequently develops multidrug resistance after years of repeated antibiotic exposure. Once chronic colonization becomes established, treatment options become increasingly limited.


Jon Koff, MD, with a patient
Credit: Robert A. Lisak,Source : Yale Medicine News Report

The Yale team treated nine adult patients using nebulized phage therapy delivered directly into the respiratory tract. According to the study, patients showed reductions in sputum P. aeruginosa levels alongside measurable improvements in lung function. Researchers also observed evidence that bacterial strains developing resistance to administered phages displayed reduced pathogenicity, an important evolutionary effect that may improve long-term clinical outcomes even when complete bacterial eradication is not achieved.

This concept, sometimes referred to as evolutionary steering, is becoming increasingly important in modern phage therapy research. Instead of viewing phage resistance solely as a therapeutic failure, researchers are attempting to exploit the biological trade-offs associated with bacterial adaptation. In some cases, mutations that protect bacteria from phage infection simultaneously reduce virulence or restore susceptibility to antibiotics.

The therapy was administered safely through inhalation, an important consideration for cystic fibrosis care where localized pulmonary delivery can maximize bacterial exposure while minimizing systemic side effects. Direct aerosolization may also improve phage penetration into mucus-associated bacterial biofilms that are often poorly accessible to conventional antibiotics.

The study reflects growing concern surrounding antimicrobial resistance in chronic pulmonary disease. Global health organizations have repeatedly warned that antibiotic-resistant infections could become one of the leading causes of mortality in coming decades, particularly as antibiotic development pipelines continue to slow.

Researchers involved in the study emphasized that phage therapy may offer a complementary approach rather than a complete replacement for antibiotics. Personalized phage selection, combined with careful monitoring of bacterial evolution during treatment, could eventually become part of a broader precision medicine strategy for managing chronic infections.

The Yale Center for Phage Biology and Therapy is now working with national and international partners to help establish coordinated phage therapy programs and expand access to compassionate-use treatments for patients with life-threatening resistant infections.

Source : Yale Medicine News Report


Comments

Post a Comment

Most Consulted Articles

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more

EMA : Guideline on quality aspects of phage therapy medicinal products

-
Image
The European Medicines Agency Publishes Draft Guideline on Quality Aspects of Phage Therapy Medicinal Products: A Landmark in the Regulation of Bacteriophage Therapeutics Introduction On 16 October 2025 , the European Medicines Agency (EMA) , through its Committee for Medicinal Products for Human Use (CHMP) and the Biologics Working Party (BWP) , adopted for public consultation the draft Guideline on Quality Aspects of Phage Therapy Medicinal Products (EMA/CHMP/BWP/1/2024) . This 15-page document represents the first comprehensive regulatory framework in the European Union specifically addressing the quality, manufacturing, and control requirements for bacteriophage-based medicinal products intended for human use. The release of this draft guideline is a significant milestone in the development of phage therapy as a legitimate, standardised, and potentially widely accessible treatment modality for bacterial infections, particularly in the context of the global antimicrobial resi...
Read more

EUCAST creates a Subcommittee on Phage susceptibility testing

-
Image
Subcommittee on Phage susceptibility testing Lytic bacteriophages, or phages, are viruses that infect and kill bacteria. Phage therapy is emerging as a promising adjuvant to traditional antimicrobials for combatting difficult-to-treat bacterial infections. However, implementation of phage-based treatments requires standardized methods for testing their efficacy to select the optimal therapeutic phages. To address this, EUCAST has established the EUCAST Phage Susceptibility Testing (PST) Subcommittee Remit of the PST Subcommittee : - Developing  standardized reference methods  to ensure uniform and reproducible  in vitro  phage susceptibility testing across laboratories worldwide, - Establishing  criteria for interpretation of PST results , providing clinicians and researchers with evidence-based guidelines to assess phage efficacy and monitor phage activity. - Promoting  quality assurance  by implementing stringent  quality control  measures ...
Read more